{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-059424","form_type":"8-K","ticker":"BRNS","cik":"0001828185","company_name":"Barinthus Biotherapeutics plc.","filed_at":"2023-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.939921+00:00","generated_at":"2026-06-15T02:44:52.444579+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vaccitech Q1 net loss $18.2M vs $2.6M income; cash $191.3M; positive HBV, HPV data","bullets":["Net loss per share $0.48 vs prior year income $0.07; revenue fell to $0.5M from $15.0M due to lower Vaxzevria royalties.","Cash $191.3M at March 31, 2023, down from $194.4M; cash runway into Q1 2025.","HBV002 trial met endpoints; meaningful HBsAg reductions; final data to be presented at EASL June 21-24.","APOLLO HPV trial showed favorable tolerability and T-cell responses; final 12-month data expected Q2 2024.","Appointed Nadège Pelletier as CSO; COO Chris Ellis to retire Oct 31, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-059424","json":"https://secwatch.observer/filing/0001104659-23-059424.json","markdown":"https://secwatch.observer/filing/0001104659-23-059424.md","text":"https://secwatch.observer/filing/0001104659-23-059424.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828185/000110465923059424/0001104659-23-059424-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828185/000110465923059424/tm2315505d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T02:44:52.444579+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"19daa1d1c8d65dec5aecd1f811a649951bf9d4e3","claim":"Barinthus Biotherapeutics plc. reported financial results for the first quarter of 2023.","evidence_excerpt":"today announced its financial results for the first quarter of 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465923059424/0001104659-23-059424-index.htm","confidence":0.97,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}